Abstract
Objective: Binge eating disorders (BED) recently become a global health care issue for clinicians with detrimental effects on all organ systems. A multidisciplinary strategy including pharmacotherapy is required for its management.
 Methods: This review is intended to comparatively evaluate the relative efficacy of different pharmacological agents in BED treatment with new therapeutic approaches, focusing on the clinical evidence and on Phase III randomized controlled trials.
 Results: Data suggest that certain treatments have advantages over placebos to reduce binge eating features; however, the small duration of such research with the lack of adequately sized trials was the major limitation in interpreting these findings. Furthermore, these medications are mostly not greatly efficient for BED associated with obesity except for topiramate, which markedly improves the features of binge episodes with weight loss. Till now, lisdexamfetamine is still the only drug with regulatory permission for BED therapy; however, its weight loss efficacy has not been established.
 Conclusion: Drugs alone or in combination approaches may be useful pharmacotherapies to yield promising outcomes acutely and over longer-term follow-up in the treatment of BED.
Highlights
The Diagnostic and Statistical Manual of Mental Disorders, fifth edition, (DSM-V) considered binge eating disorder (BED) as a distinct diagnosis of eating disorder [1]
Throughout the years, numerous guidelines and approaches have been planned for BED treatment
Several of the current BED pharmacotherapy research are overwhelmed by constraints for instance, inadequate sampling size, elevated placebo responses, elevated dropout rates, and uncertain correlation of results with clinical circumstances
Summary
The Diagnostic and Statistical Manual of Mental Disorders, fifth edition, (DSM-V) considered binge eating disorder (BED) as a distinct diagnosis of eating disorder [1]. The study showed that fluoxetine daily doses of 20 to 80 mg were well tolerated and significantly reduce the binge-eating frequency, body weight, BMI, and severity of disease along with relieving depressive symptoms. The study showed that fluvoxamine (150 mg/day) had the same efficacy of placebo in the binge eating frequency, weight changes, and improvement in depressive symptoms.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
